Related Experiment Video
Updated: Apr 27, 2026

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance
Andrew M King1, Sarah A Reid-Yu2, Wenliang Wang3
11] M.G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario L8S 4K1, Canada [2] Department of Chemistry and Chemical Biology, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
Abstract:
The emergence and spread of carbapenem-resistant Gram-negative pathogens is a global public health problem. The acquisition of metallo-β-lactamases (MBLs) such as NDM-1 is a principle contributor to the emergence of carbapenem-resistant Gram-negative pathogens that threatens the use of penicillin, cephalosporin and carbapenem antibiotics to treat infections. To date, a clinical inhibitor of MBLs that could reverse resistance and re-sensitize resistant Gram-negative pathogens to carbapenems has not been found. Here we have identified a fungal natural product, aspergillomarasmine A (AMA), that is a rapid and potent inhibitor of the NDM-1 enzyme and another clinically relevant MBL, VIM-2. AMA also fully restored the activity of meropenem against Enterobacteriaceae, Acinetobacter spp. and Pseudomonas spp. possessing either VIM or NDM-type alleles. In mice infected with NDM-1-expressing Klebsiella pneumoniae, AMA efficiently restored meropenem activity, demonstrating that a combination of AMA and a carbapenem antibiotic has therapeutic potential to address the clinical challenge of MBL-positive carbapenem-resistant Gram-negative pathogens.
Insights
A new fungal compound, aspergillomarasmine A (AMA), effectively inhibits metallo-β-lactamases (MBLs). AMA restores carbapenem antibiotic effectiveness against resistant Gram-negative pathogens, offering a potential new treatment.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Carbapenem-resistant Gram-negative pathogens pose a significant global health threat.
- Metallo-β-lactamases (MBLs), like NDM-1, are key enzymes conferring resistance to critical antibiotics.
- Existing treatments are limited due to widespread resistance.
Purpose of the Study:
- To identify novel inhibitors of MBL enzymes.
- To evaluate the potential of these inhibitors to restore antibiotic activity against resistant bacteria.
- To assess therapeutic efficacy in a preclinical model.
Main Methods:
- Screening of fungal natural products for MBL inhibitory activity.
- Biochemical assays to determine enzyme inhibition potency.
- In vitro testing of antibiotic re-sensitization in resistant Gram-negative bacteria.
- In vivo efficacy studies in a mouse infection model.
Main Results:
- Aspergillomarasmine A (AMA) was identified as a potent inhibitor of NDM-1 and VIM-2 MBLs.
- AMA restored meropenem activity against various Gram-negative pathogens, including Enterobacteriaceae, Acinetobacter spp., and Pseudomonas spp.
- Combination therapy with AMA and meropenem demonstrated therapeutic potential in a mouse model of Klebsiella pneumoniae infection.
Conclusions:
- Aspergillomarasmine A is a promising MBL inhibitor with the potential to combat carbapenem resistance.
- AMA can re-sensitize resistant Gram-negative pathogens to carbapenems.
- Combination therapy of AMA and carbapenems offers a viable strategy to treat infections caused by MBL-producing bacteria.
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Antibiotic Selection
Antimicrobial Effectiveness
Inhibitors of Bacterial Protein Synthesis

